Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 
limiting side-effects. Low expression of the CDK4/CDK6 inhibitor p16INK4a has been demonstrated in up to 90% of mesothelioma tumors.
The objective of this application as a next step in the pursuit of this long term goal is to identify stabilized peptides that will mimic the interaction between p16INK4a and CDK4/6. The central hypothesis of this proposal is that protein-protein interactions can be replicated or disrupted by stabilized peptides that have been identified via the identification of pharmacophores of small peptides that interact with CDK4/6.
The specific aims are as follows.
(1) Determine structure-function relationships of overlapping peptides derived from p16INK4a that inhibit the activity of CDK4/6 and identify stabilized peptides that inhibit CDK4/6. (2) In vitro functional studies will be used to evaluate bioactivities of stabilized peptides.
(3) In vitro ADME studies studies to evaluate the cell permeability, delivery, and efficacy of stabilized peptides.
Introduction
Mesothelioma therapy is a highly fatal disease that has poorly effective therapy with doselimiting side-effects. Low expression of the CDK4/CDK6 inhibitor p16
INK4a has been demonstrated in up to 90% of mesothelioma tumors. Replacement of p16 INK4a activity in laboratory models has demonstrated activity against CDK4 and CDK6, tumor response, and increase in survival in xenograft models. The long term goal of this laboratory is to identify key principles of drug discovery that will allow the appropriate and selective disruption or replacement of protein-protein interactions via stabilized peptides. The objective of this application as a next step in the pursuit of this long term goal is to identify stabilized peptides that will mimic the interaction between p16
INK4a and CDK4/6. The central hypothesis of this proposal is that protein-protein interactions can be replicated or disrupted by stabilized peptides that have been identified via the identification of pharmacophores of small peptides that interact with CDK4/6. The specific aims are as follows. (1) Determine structure-function relationships of overlapping peptides derived from p16
INK4a that inhibit the activity of CDK4/6 and identify stabilized peptides that inhibit CDK4/6. (2) In vitro functional studies will be used to evaluate bioactivities of stabilized peptides. (3) In vitro ADME studies to evaluate the cell permeability, delivery, and efficacy of stabilized peptides. We are using structural biology, computational modeling, in vitro efficacy, and in vitro ADME studies to design and evaluate anti-mesothelioma peptides. Work funded by this grant opportunity will lead to progress in targeted therapy with the potential for fewer side effects and higher efficacy.
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ACCOMPLISHMENTS

Major Goals of the Project (as defined in the Statement of Work)
Statement of Work
Specific Aim #1. Determine structure-function relationships of overlapping peptides derived from p16
INK4a that inhibit the activity of CDK4/6 and identify stabilized peptides that inhibit CDK4/6. The pharmacophore(s) of mutated peptides from p16
INK4a will be assessed via timeresolved fluorescent resonance energy transfer assays and nuclear magnetic resonance spectroscopy to elucidate which residues are important to bind CDK4 and/or CDK6. Stabilized peptides will be evaluated for inhibitory activity toward CDK4/6. What was accomplished under these goals? Aims 1 and Aims 2 were pursued in parallel. The % accomplishment is listed after each goal. For simplicity, we started analysis of peptides below in cellular proliferation assays due to logistics of availability of materials in the lab when starting experiments. In addition, in order to inform our decisions and analyses on design of further peptides, we wanted a sense of how well the peptides may get into cells. We focused on the following peptides in addition to a control compound, PD0332991, which is a specific competitive inhibitor of CDK4 and CDK6.
Below is a summary table of IC50 values encompassing multiple experiments (including from before and after the grant started -including all for simplicity sake and flow of the information). The first 2 columns reflect the IC 50 values derived from TR-FRET-based assays. These assays are used to evaluate the inhibition of CDK4 and CDK6 by the respective peptides or compound. Curves were fit to 3 separate multiparameter sigmoid curve equations using the program Origin. Below represents only one value of at least 3 derived from the curve fits. Of note, the assay has been quite robust in the past. When getting new supplies for this project, we did not at first see reliable curves, so a significant amount of time was spent to re-standardize the assay to increase the reliability of the assay. The values for PD0332991 had the most variability between equation fits, while the peptides were very similar across the board, aside from some variability in the CDK6 assay for the Tat 20mer. These will be re-analyzed. The 3 final columns represent the IC 50 values for the peptides or compound as tested in 3 separate mesothelioma cell lines. The 10mer, 20mer, Tat 10mer, and Tat 20mer reflect peptides that are not modified. The Tat refers to a leader sequence that is recognized to increase cell permeability of peptides. These sequences dramatically increased the efficacy of the peptides, as expected from previous studies done by Dr. Robert Kratkze. In contrast to our previous experience, the stapled peptides did not enter into the cells well. These experiments were done with a new batch DAAREGFLA(*)LVV(*)HRAGAR of peptides obtained from New England Peptide, Inc. There was significant precipitation at high concentrations (above 100 M) that was not seen with previous batches of stapled peptide. An acetyl group was added to the new batch of peptides by the company. This is done frequently by many peptide companies to increase cell permeability. We suspect that in this case, it may promote peptide aggregation. NMR experiments utilizing diffusion gradients to determine aggregation status are underway, but take time due to the technical nature and fact that they are only done by certain groups. We are receiving assistance from the Dr. Kevin Mayo group in this endeavor. New experiments will be done with non-acetylated peptides.
IC
Below is a representative inhibition curve of the Tat 20mer peptide in mesothelioma cell line 2373.
We have NMR data that was collected prior to the start of the grant that show the native 10mer is a helix (previously published. We also have data obtained prior to the grant that the native 20mer has characteristics of a helix (chemical shift data). Data analysis of the final structure is underway. In addition, we have also started NMR experiments of the stapled peptide 10mer during this grant. We have conducted a TOCSY (total correlation spectroscopy) 2-dimensional experiment that shows good resolution of the peptide in solution in the 1D aspect. Data analysis is underway and a NOESY will be done to aid in the structure determination.
In addition, we have molecular dynamics studies underway. Dr. Yuk Sham has assisted with these utilizing the Minnesota Supercomputing Institute. Even though we can have NMR-derived structural evidence that a peptide forms a helical structure, a peptide can be quite mobile in solution, potentially sampling multiple conformations. Molecular dynamics can simulate this motion, to see if the propensity is to stay in a particular conformation, or multiple conformations. One way to determine this is to analyze dihedral angles of each representative snapshot of a simulation. Below is a table from a sample snapshot from a brief simulation of the native 10mer sequence. It reflects a helical formation in 7 of the 10 residues. Simulations are underway for the other peptides at this time. We have several computer scripts underway and ready to go after a lot of work with Dr. Sham and can proceed quickly now through the peptides in a few weeks.
Western Blots performed to probe for phosphorylated Rb and actin (+/-peptide) from mesothelioma cell lines. In total, we have data for the following peptides The 4-7
th columns are what antibodies (in the case of S795, T821, and T826, antibodies to which particular phosphorylated Rb. We have listed the peptides by molecular weight. Some of the TATpeptides definitely had some activity resulting in decreased Rb phosphorylation. The native peptides did not show a decrease in Rb phosphorylation. We are still analyzing some of the stapled peptides in new experiments. INK4a , which constitute the Cdk 4/6 inhibitory sequence, were used. These included the native 10 residue sequence (FLATLVVLHR-NH 2 ) and the native 20 residue sequence (DAAREGFLATLVVLHRAGAR-NH 2 ). In addition, the native sequences were each linked to a protein transduction domain (TAT) of the HIV-1 virus (YGRKKRRQRRRGFLATLVVLHR-NH 2 and YGRKKRRQRRRGDAAREGFLATLVVLHRAGAR-NH 2 ). These four peptides were synthesized at the BioMedical Genomics Center at the University of Minnesota Cell proliferation assays. Live cells, as determined by Trypan blue dye exclusion assay, were counted on a hemocyometer and plated on 96-well plates (3000 cells/100ul/well) in the RPMI media (including supplements) 1 . After 24 hours, 10 ul of the various p16 INK4a peptides in varying concentrations were added to the wells and gently vortexed to mix. After a 72 hr incubation at 37 o C and 5% CO 2 , 10 ul of solution from Cell Counting Kit -8 (Dojindo Laboratories, Kunamoto, Japan) was added to each well and the plates were incubated for 2 hr. The plates were read at 450 nm using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Because addition of the peptides created a precipitate in the higher concentrations (i.e. 1 mM and 100 uM), which interfered with the optical readings, the contents of the wells containing a precipitate were placed in a microfuge tube and spun for 15 seconds in a microcentrifuge at 14,000 rpm. The supernatant was removed and read again in the microplate reader. The reduction in optical density represented the reduction in mitochondrial succinate dehydrogenase activity, hence the reduction in surviving cell numbers.
Kinase assay. The effect of the peptides on the kinase activity of Cdk4 and Cdk6 was evaluated using a commercially available time-resolved fluorescent resonance energy transfer (TR-FRET) assay 2 . The Adapta Universal Kinase Assay (Invitrogen Corporation, Carlsbad, CA 92008) measures kinase activity by correlating ADP formation with substrate phosphorylation. In the first phase, a kinase reaction is created by placing a kinase, the substrate (Rb), ATP, and various concentrations of a peptide into wells of a 396 well plate for 60 minutes. After the reaction, a detection solution consisting of a europium labeled anti-ADP antibody, an Alexa Fluor 647-labeled ADP tracer, and EDTA is added to the well. In the absence of an inhibitor, ADP formed by the kinase reaction will displace the labeled ADP tracer from the antibody, resulting in a decrease in the TR-FRET signal. In the presence of an inhibitor, the amount of ADP formed is reduced and the resulting intact antibody-tracer interaction results in a higher TR-FRET signal. After a 30 minute equilibration period, the signal was read using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA).
Effect of Peptides on cellular proteins.
Live cells, as tested and counted above, were plated on 6 well plates (1.0 x10 6 cells/well for 24 hour assays and 0.15x10 6 cells/well for 72 hour assays). On day 2, the cells were aspirated and usual medium with the addition of 1% DMSO and various concentrations of the different peptides were placed in the wells. The cells were incubated for either 24 or 72 hours at 37 o C and 5% CO 2 , then harvested and processed for Western blot analysis.
Immunoblotting. Cells were removed from the plates by trypsinization, washed in phosphatebuffered saline (PBS) and lysed in cold lysis buffer (50 mM Tris, pH 7.4 and 1% Triton X-100 containing 1x protease inhibitor mixture (Sigma, St. Louis, MO), 1x phosphatase inhibitor mixture (Sigma, St. Louis, MO) and 1 mM PMSF) for 10 minutes 1 . Cellular debris was pelleted by centrifugation in a microcentrifuge at 14,000 rpm at 4 o C for 10 minutes. The supernatant (lysate) was stored at -70 o C. Protein content was determined by Bio-Rad protein assay (BioRad Laboratories, Hercules, CA). For Rb Westerns, twenty to thirty micrograms of protein was mixed with equal volumes of Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA) and placed in boiling water for 2 minutes. Samples were subjected to electrophoresis on 7.5% polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes. For actin, 3 micrograms of protein was subjected to electrophoresis on 12% gels and transferred to PVDF membranes. Membranes were rinsed in Tris buffered saline with 0.05% Tween 20 (TBS-T) and incubated in blocking buffer (5% bovine serum albumin (BSA)in TBS-T) for 1 hour at 4 o C (Rb blots) or overnight (actin blots). Rb blots were then incubated in primary antibodies diluted in TBS-T containing 0.5% BSA, overnight at 4 o C. Actin blots were incubated in primary antibody for 1 hour at room temperature. The blots were washed 6x with TBS-T and then incubated with an appropriate secondary antibody, diluted in TBS-T for 1 hour at room temperature. Following 6 washes in TBS-T, blots were developed with a chemiluminescence reagent (Pierce ECL Western Blotting Substrate, Thermo Scientific, Rockford, IL, USA or Amersham ECL Prime Western Blotting Detection Reagent, GE Healthcare, Buckinghamshire, UK) and exposed to xray films. X-ray film was processed on an Agfa-CP1000 developer.
NMR. Two-dimensional NMR spectra of the most active peptide derived from peptides identified in Aims 1a and 1b are being obtained [3] [4] [5] [6] [7] [8] . TOCSY (total correlational spectroscopy) spectra (to assign peaks to specific amino acids) 41 and NOESY (nuclear Overhauser Effect Spectroscopy) spectra (to determine through-space interactions < 5 Å) will be obtained and used to computationally model the peptide structure 42 .The program NMRPipe 43 will be used to process data, and the program Sparky 44 will be used to evaluate spectra and assign peaks. The program X-PLOR will then be used to perform structural calculations and refinements based on NOE internuclear distant constraints, as mentioned above 45 . The result of this subaim will yield molecular models of the three-dimensional structure of the peptides based on the NMR-derived data.
What opportunities for training and professional development has the project provided? Coursework: In the spring semester of 2014, I took the graduate level course "Biochemical Aspects of Normal and Abnormal Cell Growth and Cell Death" at the University of Minnesota (offered by the Microbiology, Immunology, and Cancer Biology graduate program). I took this course for credit (2 credit hours) and received a grade of A. 
IMPACT What was the impact on the development of the principal disciplines of the project?
We have identified that TAT-p16 peptides have good potency against CDK4. These were nearly as potent against mesothelioma cell lines as PD0332991 (palbociclib). Stapled peptides had less efficacy against CDK4/6 than anticipated. We suspect this may be due to the olefin tether interfering with the binding of the peptide to CDK4/6. In addition, the peptides did not enter into the cells as they previously have. That has lead us to hypothesize that we need to identify more properties with mesothelioma cell biology before designing several new peptides. We are continuing to analyze peptide mutations now.
What was the impact on other disciplines?
Nothing to report.
What was the impact on technology transfer?
What was the impact on society beyond science and technology?
Nothing to report CHANGES/PROBLEMS Changes in approach or reasons for change.
We have not changed any of the aims. Due to some difficulty with solubility and also with developing the necessary programs for molecular dynamics studies, we chose to also pursue parts of aim 2 in parallel with the goal of still having the vast majority of aim 1 finished by the 1.5 year mark or so.
Actual or anticipated problems or delays and actions or plans to resolve them.
Initially, we had more difficulty with usual with solubility for stapled peptides. It appears to have aggregated in solution. We have been systematically adjusting solution conditions to see if this affects the peptides. Of note, the company placed acetyl groups on the n-terminus as part of protocol. Our previous peptides did not have these. We are in the midst of obtaining new peptides to determine if this will affect solubility. We are also working with the Kevin Mayo lab at the University of Minnesota in conducting NMR diffusion gradient experiments to determine aggregation properties (this technique can help to establish the presence of dimers, tetramers, etc. in certain situations). However, this is a specialized technique that takes time to establish for each peptide.
We are moving forward with molecular dynamics studies steadily now that we have most of the program issues worked out in Desmond at the University of Minnesota Supercomputing Institute. The molecular dynamics were a bit delayed due to needing to get special access to the Supercomputing Institute and to get the appropriate amount of computer time. It also took some time to develop software plug-in scripts to work with the program Desmond. Now that is going well and we should have several more peptides analyzed in a few weeks.
We have also had some difficulty with immunoblotting recently -this seems to have been due to age of some of the membranes needed and need for new lysate -these are working much better now.
The primary mentor, Robert Kratzke, M.D., also was unexpectedly gone for just short of 3 months in the spring of 2014 due to unusual circumstances. Prior to that time and after, the PI interacted regularly with Dr. Kratzke. He is now back working full time.
Changes that had a significant impact on expenditures.
We have carried over a small amount of funding from year 1 to year 2 due to issues with peptide solubility. It is anticipated that with changes in protocol that these studies will be finished in the first half of year two. This was a very small percent of the budget.
Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents. Not applicable and nothing to report.
PRODUCTS
The PI produced one journal article, one poster at a major meeting, and two oral presentations since beginning the grant. They are listed below. The manuscript is in the appendix. Mesothelioma is a highly fatal disease that has poorly effective therapy with dose-limiting sideeffects. Low expression of the endogenous CDK4/CDK6 inhibitor, p16INK4a, has been demonstrated in up to 90% of mesothelioma tumors. Replacement of p16INK4a activity via gene therapy in laboratory models has demonstrated activity against CDK4 and CDK6, tumor response, and an increase in survival in xenograft models. Two truncated peptides (FLDTLVVLHR and DAAREGFLDTLVVLHRAGAR) derived from the 3rd anykyrin repeat of p16INK4a have been shown to exhibit similar activity to the full-length protein. An isolated 10mer peptide has also been shown to maintain its native helical structure away from its full length protein. Hypothesis: Protein-protein interactions between CDK4/6 and p16INK4a can be replicated or disrupted by engineered stabilized helical peptides identified from shortened peptides that interact with CDK4/6. Results and Discussion: We evaluated the bioactivities of several truncated peptides against CDK4/6 and mesothelioma cell lines. The IC50 values against CDK4 and CDK6 for the native peptides ranged from 14.6 μM to 21.2 μM. Peptides with a TAT-leader sequence (YGRKKRRQRRR) bound to the amino-terminal end exhibit a wider range of IC50 activities from 860 nM to 257 μM. Stabilized helical peptide derivatives (one olefin linker per peptide, i,i+4) were also studied, and the IC50 values ranged from 49 -105 μM. Against mesothelioma cell lines, the IC50 values against TAT-derived peptides ranged from 37.6 to 88.2 μM, while IC50 values for all the other peptides were > 1mM. We are currently engaged in molecular dynamics simulations to determine whether a correlation persists between the percent helicity of these peptides and its bioactivity. We anticipate such a correlation will greatly enrich our understanding in the transient structural nature of our peptides and will provide an improved platform for further design of stabilized helical peptide candidates. 
APPENDICES
